Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

202271 citationsJournal Articlehybrid Open Access

Authors

Over 2 years, tralokinumab was well tolerated and maintained long-term control of AD signs and symptoms.

Good health and well-being

Published in: Journal of the American Academy of Dermatology

Volume 87, Issue 4, pp. 815-824

Field-Weighted Citation Impact: 14.19